Value Sense
BSX
Boston Scientific Corporation (BSX)
Last Price$104.91.0%
Market Cap$154.5B
LTM P/E
83.5x
EPS growth
59.1%
PEGY
1.4x
Peter Lynch Fair Value
$74.2
Overvalued (Peter Lynch formula)
(29.2%)
Stock quality
7/10
Good
BSX
is 67.4% overvalued
learn more -->
50+
undervalued stocks
Start beating the S&P 500

BSX Peter Lynch Fair Value

Peter Lynch Fair Value Assumptions

as of Mar 10, 2025
LTM P/E
83.5x
EPS growth
59.1%
Dividend Yield
0.0%
PEGY
1.4x
Last share price
$104.9
Peter Lynch Fair Value
$74.2
29.2% overvalued

Peter Lynch Fair Value Calculation

PEGY
1.4x
=
LTM P/E
83.5x
/
(
EPS growth
59.10%
+
Dividend yield
0.01%
)
Peter Lynch
Fair Value
$74.2
=
Last share price
$104.9
/
PEGY
1.4x

Best stock ideas on the market right now

With Value Sense, you can find undervalued stocks list with intrinsic value. Discover more stock market investment ideas.

Undervalued stocks right now

Undervalued stocks right now

Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.

3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Low P/E stocks

Low P/E stocks

Explore the best low P/E stocks to buy in 2025, featuring top companies trading at low P/E ratios.

3M Return 7.5%
S&P Outperformance -5.5%
Next 3M Predicted Return 10.2%
Undervalued dividend stocks

Undervalued dividend stocks

Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.

3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%

BSX EPS growth & Dividend Yield

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
EPS growth
Dividend Yield

BSX vs Peer Set: Peter Lynch Fair Value Comparison

General

PETER LYNCH FAIR VALUE

Financial metrics

Company name

Undervaluation / Overvaluation

Revenue growth

EBITDA margin

Net Income margin

Boston Scientific Corporation logo
Boston Scientific CorporationBSX
(29.2%)
17.6%
16.7%
11.1%
Median Peer Set
4.1%
126.3%
12.7%
Stryker Corporation logo
Stryker CorporationSYK
(22.9%)
10.2%
(5.8%)
13.2%
STERIS plc logo
STERIS plcSTE
34.4%
3.6%
257.9%
7.4%
Align Technology, Inc. logo
Align Technology, Inc.ALGN
1.5%
3.4%
26.0%
11.5%
Medtronic plc logo
Medtronic plcMDT
69.8%
3.6%
(2.1%)
11.4%
Zimmer Biomet Holdings, Inc. logo
Zimmer Biomet Holdings, Inc.ZBH
1.4%
6.5%
253.2%
13.8%
Insulet Corporation logo
Insulet CorporationPODD
(67.3%)
30.0%
4,364.6%
12.2%
DexCom, Inc. logo
DexCom, Inc.DXCM
(48.1%)
11.3%
(1.4%)
14.3%
Abbott Laboratories logo
Abbott LaboratoriesABT
(169.3%)
4.6%
134.5%
31.9%
Edwards Lifesciences Corporation logo
Edwards Lifesciences CorporationEW
(457.4%)
(9.4%)
202.2%
76.7%
Koninklijke Philips N.V. logo
Koninklijke Philips N.V.PHG
N/A
(0.8%)
118.1%
(3.9%)

Explore more intrinsic value tools hub for BSX

Margin of safety
Ben Graham Fair Value
Earnings growth model
Discount rate
Peter Lynch charts
Reverse DCF
Earnings Power Value
Intrinsic Value
DCF value calculator
Relative Value

FAQ

What is Boston Scientific Corporation fair value by Peter Lynch formula?

As of Mar 03, 2025, Boston Scientific Corporation's fair value using the Peter Lynch formula is $74.2 per share. The current price of $104.9 suggests Boston Scientific Corporation may be overvalued by this metric.

What is Boston Scientific Corporation Price to Earnings (P/E) ratio?

As of Mar 03, 2025, Boston Scientific Corporation's P/E ratio is 83.5x. This is calculated by dividing the current share price of $104.9 by the Earnings per Share (EPS) for the trailing twelve months, which is $0.9. The P/E ratio indicates how much investors are willing to pay for each dollar of earnings.

What is Boston Scientific Corporation earnings per share (EPS)?

Boston Scientific Corporation earnings per share (EPS) for the twelve months ending Mar 03, 2025, was $0.9, a 59.1% growth year-over-year.